公开(公告)号：US5604216A

公开(公告)日：1997-02-18

申请号：US178553

申请日：1994-01-06

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K8/30 ,  A61K8/00 ,  A61K8/63 ,  A61K31/565 ,  A61K31/575 ,  A61P9/00 ,  A61P9/10 ,  A61P25/00 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61Q19/00 ,  C07J9/00 ,  A61K31/56

CPC classification number: A61K31/565

Abstract: Pharmaceutical and nutritional compositions are disclosed containing, in association with a suitable diluent or carrier, at least 10% by weight of a cholesterol fatty acid ester where the fatty acid is gamma-linolenic acid, dihomo-gamma-linolenic acid, adrenic acid, the 22:5 n-6 acid, stearidonic acid, the 20:4 n-3 acid, eicosapentaenoic acid, docosahexaenoic acid, the 22:5 n-3 acid or columbinic acid. Novel cholesterol columbinic acid esters are described.

Abstract translation: 公开的药物和营养组合物包含与合适的稀释剂或载体相结合的至少10重量％的胆固醇脂肪酸酯，其中脂肪酸是γ-亚麻酸，二高-γ-亚麻酸，肾上腺素， 22：5 n-6酸，十八碳四烯酸，20：4n-3酸，二十碳五烯酸，二十二碳六烯酸，22：5 n-3酸或哥伦比亚酸。 描述了新型胆固醇骨架酸酯。

公开(公告)号：US5603959A

公开(公告)日：1997-02-18

申请号：US392628

申请日：1995-02-22

Applicant: David F. Horrobin ,  Philip Knowles

Inventor： David F. Horrobin ,  Philip Knowles

IPC: A61K45/00 ,  A61K31/215 ,  A61K31/235 ,  A61K31/405 ,  A61K31/60 ,  A61P13/02 ,  A61P15/00 ,  A61P25/28 ,  A61P29/00 ,  C07C69/86 ,  C07C69/90 ,  C07D209/28 ,  A61K9/14

CPC classification number: C07C69/84 ,  C07C69/86 ,  C07D209/28

Abstract: An NSAID in the form of a compound with an essential fatty acid or essential fatty acid alcohol, particularly an NSAID as listed in categories 1 to 9 herein. Further, a method of preparation of a medicament for the treatment including prophylatic treatment of rheumatoid arthritis, osteoarthritis and related disorders; dysmenorrhoea; dementias, including Alzheimer's disease; or any other inflammatory or other conditions specified herein, wherein the said NSAID is used.

Abstract translation: 具有必需脂肪酸或必需脂肪酸醇的化合物形式的NSAID，特别是本文第1至9类中列出的NSAID。 此外，制备用于治疗的药物的方法，包括类风湿性关节炎的预防治疗，骨关节炎和相关疾病; 痛经 痴呆症，包括阿尔茨海默病; 或本文规定的任何其它炎症或其它病症，其中使用所述NSAID。

公开(公告)号：US5516800A

公开(公告)日：1996-05-14

申请号：US154481

申请日：1993-11-19

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61P25/18

CPC classification number: A61K31/20

Abstract: The negative symptoms of schizophrenia and/or low cell membrane levels of EFAs may be treated with a combination of arachidonic acid and docosahexaenoic acid.

Abstract translation: 精神分裂症和/或EFAs的低细胞膜水平的阴性症状可以用花生四烯酸和二十二碳六烯酸的组合来治疗。

公开(公告)号：US5378732A

公开(公告)日：1995-01-03

申请号：US981116

申请日：1992-11-25

Applicant: David F. Horrobin ,  John C. M. Stewart

Inventor： David F. Horrobin ,  John C. M. Stewart

IPC: A61K31/20 ,  A61K31/202 ,  A61P9/00 ,  A61P9/10 ,  C07C57/03 ,  C07C57/12

CPC classification number: A61K31/20 ,  Y10S514/824

Abstract: Gamma-linolenic acid and/or dihomo-gamma-linolenic acid is used in a medicament for reducing the rate of reocclusion of an artery from which an occlusion or other blockage has been removed, or for preventing occlusion of peripheral or coronary arteries. The medicament may also comprise eicosapentaenoic acid.

Abstract translation: γ-亚麻酸和/或二 - γ-亚麻酸用于降低动脉阻塞或其他阻塞已被除去的动脉或用于防止外周或冠状动脉闭塞的再闭塞速率的药物中。 药物还可以包含二十碳五烯酸。

公开(公告)号：US5318991A

公开(公告)日：1994-06-07

申请号：US51436

申请日：1993-04-22

Applicant: David F. Horrobin ,  Alfred C. Buck

Inventor： David F. Horrobin ,  Alfred C. Buck

IPC: A61K31/20 ,  A61K31/202 ,  A61P3/00 ,  A61P3/14 ,  A61P13/02 ,  A61P15/00 ,  A61P43/00

CPC classification number: A61K31/20

Abstract: Reduction of urinary calcium excretion in humans or animals by the administration of GLA or DGLA as much or in salt or other pharmacologically acceptable form, optionally in association with EPA, DHA or other EFA in similar forms, is also useful in the treatment of nephrocalcinosis, renal stones and osteoporosis.

Abstract translation: 通过给予GLA或DGLA或以任何与EPA，DHA或类似形式的其他EFA相关联的盐或其它药学上可接受的形式来减少人体或动物中的尿钙排泄也可用于治疗肾病， 肾结石和骨质疏松症。

公开(公告)号：US5276020A

公开(公告)日：1994-01-04

申请号：US990190

申请日：1992-12-14

Applicant: David F. Horrobin ,  John C. M. Stewart ,  Michael D. Winther

Inventor： David F. Horrobin ,  John C. M. Stewart ,  Michael D. Winther

IPC: C07D473/18 ,  A61K31/00 ,  A61K31/505 ,  A61K31/52 ,  A61K31/522 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7052 ,  A61K31/7064 ,  A61K31/7072 ,  A61P31/00 ,  A61P31/12 ,  C07D405/04 ,  C07D473/00 ,  C07H19/06 ,  C07H19/073 ,  C07H19/16 ,  C07H17/00

CPC classification number: C07D473/00 ,  C07H19/06 ,  C07H19/16

Abstract: Anti-virals wherein a linoleyl, gamma-linolenyl or other unsaturated long chain fatty acyl group is borne directly on a hydroxy or amino group of the sugar/sugar analogue or heterocyclic moiety of a nucleoside or nucleoside analogue.

Abstract translation: 其中亚油酰基，γ-亚麻醇基或其它不饱和长链脂肪酰基直接承载在核苷或核苷类似物的糖/糖类似物或杂环部分的羟基或氨基上的抗病毒剂。

公开(公告)号：US5246726A

公开(公告)日：1993-09-21

申请号：US871761

申请日：1992-04-21

Applicant: David F. Horrobin ,  Michel E. Begin

Inventor： David F. Horrobin ,  Michel E. Begin

IPC: A61K31/20 ,  A61K31/23 ,  A61K33/26

CPC classification number: A61K31/20 ,  A61K31/23 ,  A61K33/26

Abstract: Pharmaceutically acceptable compositions of one or more n-6 or n-3 essential fatty acids, particularly gamma-linolenic acid, dihomo-gamma-linolenic acid, or eicosapentaenoic acid, and assimilable iron compounds, in dosage unit form optionally with a diluent or carrier, said acids being present as such or as derivatives convertible in the body thereto and the amounts of said acids or derivatives being 1 mg to 100 g (calculated as gamma-linolenic acid) and of said iron compounds 0.1 mg to 10 g (calculated as iron) or submultiples of said amounts convenient for daily administration thereof.

Abstract translation: 一种或多种n-6或n-3必需脂肪酸，特别是γ-亚麻酸，二氢-γ-亚麻酸或二十碳五烯酸和可同化铁化合物的药学上可接受的组合物以剂量单位形式任选地含有稀释剂或载体 所述酸以本身的形式存在或作为在体内可转化为衍生物的衍生物，所述酸或衍生物的量为1mg至100g（以γ-亚麻酸计算）和所述铁化合物0.1mg至10g（以 铁）或所述量的次数便于日常给药。

公开(公告)号：US5198468A

公开(公告)日：1993-03-30

申请号：US717862

申请日：1991-06-19

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20

CPC classification number: A61K31/20

Abstract: Treatment or prevention of memory loss with a medicament consisting of an n-6 essential fatty acid selected from GLA, DGLA, AA, adrenic acid and the 22:5 n-6 acid and an n-3 essential fatty acid selected from the 18:4 n-3 and 20:4 n-3 acids, EPA, the 22:5 n-3 acid and DHA.

Abstract translation: 用由选自GLA，DGLA，AA，肾上腺素和22：5n-6酸和n-3必需脂肪酸的n-6必需脂肪酸组成的药物治疗或预防记忆丧失，其选自18： 4 n-3和20：4 n-3酸，EPA，22：5 n-3酸和DHA。

公开(公告)号：US5145686A

公开(公告)日：1992-09-08

申请号：US818501

申请日：1992-01-08

Applicant: David F. Horrobin ,  Julian Lieb

Inventor： David F. Horrobin ,  Julian Lieb

IPC: A61K8/19 ,  A61K8/36 ,  A61K8/362 ,  A61K8/365 ,  A61K8/368 ,  A61K8/67 ,  A61K8/92 ,  A61K31/19 ,  A61K31/195 ,  A61K31/20 ,  A61K33/00 ,  A61K33/30 ,  A61K36/185 ,  A61K45/06 ,  A61Q5/00 ,  A61Q19/00

CPC classification number: A61K45/06 ,  A61K31/195 ,  A61K31/20 ,  A61K33/00 ,  A61K33/30 ,  A61K36/185 ,  A61K8/19 ,  A61K8/361 ,  A61K8/362 ,  A61K8/365 ,  A61K8/368 ,  A61K8/67 ,  A61K8/922 ,  A61Q19/00 ,  A61Q5/00 ,  A61K2800/782

Abstract: Topical pharmaceutical compositions for the treatment of lesions of the skin or mucous membranes containing a physiologically acceptable lithium salt together with at least one substance selected from substances capable of selectively increasing the in vivo level of E-series prostaglandins, substances capable of inhibiting cyclooxygenase enzyme, substances capable of inhibiting the formation of lipoxygenase products, and lysine.

Abstract translation: 用于治疗含有生理上可接受的锂盐的皮肤或粘膜损伤的局部药物组合物以及选自能够选择性地增加E系列前列腺素的体内水平的物质，能够抑制环加氧酶的物质的至少一种物质， 能够抑制脂氧合酶产物形成的物质和赖氨酸。

公开(公告)号：US4868212A

公开(公告)日：1989-09-19

申请号：US307952

申请日：1989-02-09

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A23D9/00 ,  A23L1/30 ,  A23L1/325 ,  A23L1/48 ,  A61K31/16 ,  A61K31/20 ,  A61K31/22 ,  A61K31/23 ,  A61K31/557 ,  A61K35/56 ,  A61K35/60 ,  A61K36/00 ,  A61K36/185 ,  A61K38/00 ,  A61P3/08 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/30 ,  A61P27/16 ,  A61P35/00 ,  A61P37/08

CPC classification number: A61K35/60 ,  A23D9/00 ,  A61K31/20 ,  A61K31/23 ,  A61K31/557 ,  A61K36/185 ,  Y10S514/861 ,  Y10S514/866

Abstract: A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.